FDA Expands Approval for Tocilizumab Biosimilar to Treat CRS FDA expands tocilizumab-anoh's indication for treating cytokine release syndrome, enhancing treatment options for patients undergoing CAR T-cell therapy.

La #FDA des USA a approuvé une indication élargie du #Tocilizumab (#Avtozma), un #Biosimilaire du #Tocilizumab ( #Actemra), pour le traitement du syndrome de libération de #Cytokines ( #SRC) chez les adultes et les patients pédiatriques âgés de 2 ans et plus.
www.targetedonc.com/view/fda-exp...

MS patients suffer side-effects after NHS England switches to cheaper drug Scores of people experience complications after change from Tysabri to Tyruko as part of NHS drive to save money

#SEP #biosimilaire #vigilance
www.theguardian.com/society/2025...